Stereotactic ablative radiation therapy for primary lung tumors.
Stereotactic ablative radiotherapy, also known as stereotactic body radiation therapy, has been developed as an innovative therapy for stage I non-small cell lung cancer and has now emerged as a standard treatment option for medically inoperable patients through careful analysis utilizing prospective, multi-institutional trials. This article reviews and updates the evidence for use of stereotactic ablative radiotherapy in medically inoperable patients with stage I lung cancer, its extension of use to medically operable patients, and the toxicities associated with this emerging technique.
Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
John H
JH
Heinzerling
Brian
B
Kavanagh
Robert D
RD
Timmerman
D002289:Carcinoma, Non-Small-Cell Lung / Q000473:pathology / Q000601:surgery*; D002986:Clinical Trials as Topic; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology / Q000601:surgery*; D009367:Neoplasm Staging; D016634:Radiosurgery